Research: Opioids, Surgery & Cognitive Decline in Aging

If you or a loved one has ever noticed troubling memory lapses or mental fog following a surgical procedure — a phenomenon physicians often call postoperative cognitive dysfunction (POCD) — emerging preclinical research may begin to explain why. A 2026 study published in Brain, Behavior, and Immunity by Muscat, Deems, Alvarez, and colleagues suggests that opioid use during and after surgery may drive lasting cognitive impairment in aged individuals by disrupting energy production in brain cells — specifically within the hippocampus, the brain's primary memory center. While this research was conducted in aged rats and human studies are needed to confirm these findings, the mechanistic insights it offers are significant and worth understanding.

What This Study Found

Using an aged rat model designed to mimic surgical procedures with perioperative morphine administration, researchers set out to understand how opioids contribute to persistent memory deficits after surgery — not merely whether they do. The results pointed toward a specific and targetable culprit: hippocampal mitochondrial dysfunction.

Importantly, the researchers found that the memory impairments observed in surgery-plus-morphine animals were not explained by systemic illness or widespread degeneration of nerve cell branches (dendrites). Instead, the study identified a more nuanced and selective pattern of damage. Animals treated with surgery and morphine showed reductions in specific dendritic spine subtypes — the small structural protrusions on neurons that are closely associated with synaptic stability and memory formation. They also demonstrated impaired late-phase long-term potentiation (LTP), which is the cellular mechanism the brain uses to consolidate and strengthen memories.

Compounding these synaptic changes, researchers found that surgery-and-morphine-treated animals had blunted upregulation of GluA1, a critical subunit of AMPA receptors that plays a key role in learning-dependent synaptic plasticity. Elevated levels of neurofilament light chain (Nf-L) — a biomarker of axonal injury detectable in the bloodstream — were also observed, suggesting sustained perturbation of nerve fiber integrity.

At the mitochondrial level, the study found persistent dysfunction characterized by impaired oxidative phosphorylation (the process by which mitochondria generate cellular energy), reduced respiratory reserve capacity (the mitochondria's ability to ramp up energy output under stress), and increased DNA oxidation — a marker of oxidative damage. Crucially, these mitochondrial deficits were specific to the hippocampus and were not observed in liver tissue, suggesting the brain is selectively vulnerable rather than experiencing a body-wide mitochondrial collapse.

The researchers then tested two therapeutic strategies. First, pharmacological inhibition of TLR4 signaling — a key pathway in neuroinflammation — at the time of surgery attenuated oxidative stress and partially restored mitochondrial function, implicating early inflammatory signaling in the cascade that leads to long-term mitochondrial damage. Second, and perhaps most striking, targeted mitochondrial rejuvenation using the peptide SS-31 administered four weeks after surgery robustly rescued hippocampal-dependent memory and normalized mitochondrial respiratory function in aged rats, even in the presence of persistently elevated DNA oxidation and Nf-L levels. The study suggests that restoring mitochondrial energy capacity may be sufficient to recover cognitive function even after injury markers remain elevated.

Clinical Significance

POCD is far from a rare or minor concern. Older surgical patients face a disproportionate risk of experiencing lasting declines in memory, attention, and executive function following procedures — complications that can significantly diminish quality of life and independence. Despite the well-documented prevalence of POCD, particularly in aging populations, the precise biological mechanisms have remained poorly understood, making it difficult to develop targeted interventions.

This research is significant because it identifies hippocampal mitochondrial dysfunction as a key mechanistic substrate underlying opioid-associated cognitive decline after surgery in an aged animal model. By mapping the pathway from early neuroinflammatory signaling (TLR4 activation) through synaptic instability to mitochondrial energy failure, the study provides a clearer roadmap for potential therapeutic intervention.

The finding that SS-31 — a mitochondria-targeting peptide — could rescue memory function even when administered a month after surgery is particularly noteworthy. It raises the possibility that there may be a therapeutic window for intervention after the damaging event, not just at the time of surgery. Researchers emphasize, however, that these findings are preclinical, and well-designed human clinical trials will be essential to determine whether these mechanisms and therapeutic strategies translate to human patients.

Current Access and Compliance Context

SS-31, also known as elamipretide, is a mitochondria-targeted tetrapeptide that has attracted considerable scientific interest for its ability to stabilize mitochondrial membrane structure and support oxidative phosphorylation. It is currently being studied in clinical trials for several conditions involving mitochondrial dysfunction, including heart failure and age-related eye disease. As of the time of this writing, SS-31 is not approved by the FDA for general clinical use and is available in research and certain compounding contexts only.

Any use of SS-31 or related peptide therapies should occur only under the supervision of a qualified and knowledgeable healthcare provider. Patients and clinicians interested in mitochondrial-targeted therapies should remain closely attuned to evolving regulatory guidance, institutional review, and the developing clinical evidence base. Self-administration without medical oversight is strongly discouraged.

What Patients Should Know

If you are an older adult facing an upcoming surgical procedure — especially one involving opioid pain management — this research underscores the importance of an open and proactive conversation with your surgical team. While the findings are from an animal model and cannot yet be directly applied to clinical practice in humans, they highlight several areas worth discussing with your provider:

• Opioid-sparing strategies: Ask your anesthesiologist or surgeon whether multimodal analgesia approaches — which minimize opioid exposure — may be appropriate for your procedure and risk profile.
• Cognitive monitoring: Patients at higher risk of POCD (older age, pre-existing mild cognitive impairment, longer procedures) may benefit from baseline cognitive assessment and post-operative follow-up.
• Neuroinflammation and brain health: Emerging evidence suggests that perioperative neuroinflammation plays a meaningful role in cognitive outcomes. Lifestyle factors that support mitochondrial health and reduce systemic inflammation — including physical activity, sleep hygiene, and nutritional adequacy — may be worth optimizing before and after surgery, though their direct impact on POCD has not been established by this study.
• Peptide research: If you are interested in mitochondrial-targeted peptide therapies such as SS-31, speak with a physician who is knowledgeable about the current evidence and legal access pathways. Do not attempt to source or self-administer any peptide compound outside of medical supervision.

It is also worth noting that the biomarker of axonal injury identified in this study — neurofilament light chain (Nf-L) — is increasingly available as a clinical blood test in specialized settings. As research advances, monitoring tools like Nf-L may eventually help identify patients at elevated risk for POCD or track treatment responses, though this application remains investigational.

Conclusion

The 2026 study by Muscat and colleagues represents a meaningful advance in our understanding of why older surgical patients are vulnerable to lasting cognitive decline following opioid-assisted procedures. By identifying sustained hippocampal mitochondrial dysfunction as a central mechanistic driver — and by demonstrating that a mitochondria-targeting peptide could rescue memory function in an aged animal model — the research opens compelling new avenues for therapeutic development. Human trials are the necessary next step.

If you are interested in learning more about peptide research and speaking with a physician who stays current with the evolving science of cognitive health, mitochondrial function, and evidence-based peptide therapies, visit peptideassociation.org/find-a-doctor to connect with a qualified provider in your area.

---

Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The research discussed was conducted in aged rats; findings may not directly apply to humans. Always consult a qualified healthcare professional before making any decisions related to surgery, pain management, cognitive health, or the use of any therapeutic agent, including peptides.

---

AMA Citation: Muscat SM, Deems NP, Alvarez BD, et al. Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats. Brain Behav Immun. 2026;(published online ahead of print). doi:10.1016/j.bbi.2026.106942. PMID: 42546889.